Wegovy before and after: what clinical results look like in practice

What do before-and-after results from Wegovy trials actually show?

The clearest evidence comes from the STEP 1 trial, published in the New England Journal of Medicine. Adults with obesity who took semaglutide 2.4mg weekly for 68 weeks lost an average of 14.9% of their starting weight, compared with 2.6% in the placebo group. In concrete terms, someone starting at 100 kg would have lost roughly 15 kg on average. About one in three participants lost more than 20%, but a meaningful proportion lost less than 10%. That spread matters. Before-and-after photos shared online tend to reflect the high-responders rather than the average, which is why the trial figure is a more useful reference point than any individual transformation you might come across.

The picture shifted again with the 7.2mg Wegovy pen, approved by the MHRA in April 2026. Trial data for that higher dose reported around 20.7% average weight loss over 72 weeks, a result that approaches what has been seen with tirzepatide. If you're exploring the comparison between the two treatments, our page on how Wegovy works and where it sits clinically covers that in more detail.

How quickly does the before-and-after change happen, and why isn't the first month dramatic?

Most people starting Wegovy notice very little weight change in the opening four weeks. The starting dose is 0.25mg (a tolerability level, not the therapeutic maintenance dose) and it is stepped up through 0.5mg, 1mg and 1.7mg before reaching 2.4mg. Each step takes roughly four weeks, so the body is still adjusting to the medicine during the early phase. Appetite suppression tends to become more noticeable as the dose increases. This is one reason before-and-after photos taken at one month look quite different from those taken at six months or a year.

A practical habit worth building: weigh yourself at the same time of day, on the same scales, in similar clothing, once a week. That consistency means your own before-and-after data is actually comparable from one check to the next, daily fluctuations of 1–2 kg from water, food and hormones are normal and do not reflect fat change. For a more detailed look at the monthly progression, our overview of what to expect from Wegovy in the first month walks through what is and isn't typical at that early stage.

For a broader look at how long Wegovy takes to work across the full titration schedule, that page sets out the realistic timeline week by week.

What affects how much weight someone loses before and after Wegovy?

Individual response to semaglutide varies more than many people expect. Starting BMI plays a role, those with a higher starting weight often lose more in absolute terms, though percentage loss varies. Adherence to a reduced-calorie diet and regular physical activity consistently amplifies results in trial data; Wegovy is licensed alongside lifestyle changes, not as a replacement for them. Dose tolerance matters too: some people find GI side effects (nausea, loose stools, fatigue) limit how quickly they can titrate, and staying on a lower dose for longer can slow progress.

Genetics, gut hormone sensitivity and metabolic history all influence response in ways that cannot be predicted before starting. Stopping treatment is also a key variable: weight tends to return when semaglutide is discontinued without the lifestyle habits that support it. Results in people who completed the full STEP 1 trial reflect sustained treatment, a before-and-after at six months does not represent the same commitment as one at eighteen months. If you are interested in how outcomes compare between men and women, our piece on before-and-after results in men on Wegovy covers what the data suggests about sex differences in response.

You can also read about before-and-after data for semaglutide more broadly, including how trial populations and doses affect the numbers quoted.

Is what you see in UK before-and-after photos realistic for most people?

Social media before-and-after content (even when genuine) is subject to selection bias. People who have lost 25–30% of their body weight are more likely to share their results than people who lost 8%. Lighting, posture, clothing and time elapsed between photos all change the apparent result. None of this means the medicine is not effective; the trial data is robust. It does mean that using someone else's photos as your personal benchmark tends to create unrealistic expectations that make the actual outcome feel like a failure even when it isn't.

UK before-and-after experience is also shaped by the titration schedule, the NHS and private prescribers here follow the same licensed escalation pattern, so results in Wegovy UK before-and-after contexts should broadly reflect the trial data. What varies is how well lifestyle support is maintained alongside the medicine. For a fuller picture of what outcomes look like including the full weight-loss data, our Wegovy results and before-and-after overview goes into greater depth on the trial evidence and what it means practically. If you have questions about cost or how a private consultation compares to NHS access, our guide to Wegovy pricing in the UK covers what legitimate treatment involves.

Wegovy is a prescription medicine. A prescriber at nume reviews every consultation personally (not software) before any treatment is approved. If you'd like to understand whether it might be appropriate for you, speak to our prescribers through a free consultation.